# Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

> **NCT00193024** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 90 (—)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Epirubicin

## Key facts

- **NCT ID:** NCT00193024
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-09
- **Primary completion:** 2003-10
- **Final completion:** 2004-10
- **Target enrollment:** 90 (—)
- **Last updated:** 2011-05-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193024, "Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00193024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*